Profusa, Inc. (NASDAQ:PFSA) Short Interest Update

Profusa, Inc. (NASDAQ:PFSA) was the recipient of a significant drop in short interest in May. As of May 15th, there was short interest totaling 268,839 shares, a drop of 59.6% from the April 30th total of 665,135 shares. Currently, 6.5% of the shares of the stock are short sold. Based on an average trading volume of 243,966 shares, the days-to-cover ratio is presently 1.1 days.

Profusa Stock Down 1.5%

NASDAQ:PFSA traded down $0.01 during trading hours on Friday, hitting $0.35. The company had a trading volume of 185,419 shares, compared to its average volume of 232,246. The firm has a market cap of $1.65 million, a P/E ratio of 0.00 and a beta of 0.35. The company’s 50-day simple moving average is $0.60. Profusa has a 52 week low of $0.34 and a 52 week high of $180.00.

Profusa (NASDAQ:PFSA) last released its quarterly earnings results on Friday, May 15th. The company reported ($2.05) earnings per share for the quarter.

Wall Street Analysts Forecast Growth

PFSA has been the topic of several research reports. Wall Street Zen raised shares of Profusa from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Profusa in a report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

About Profusa

Profusa develops implantable, tissue-integrated biosensors and associated reader technology designed to provide continuous, real-time monitoring of physiological biomarkers. Its platform uses a biocompatible, porous hydrogel sensor that is placed under the skin via a minimally invasive procedure and becomes perfused with tissue; an external optical reader interrogates the sensor to convert fluorescent or optical signals into quantitative measurements such as local tissue oxygen levels. The company’s approach emphasizes long-duration sensing from a single implanted device rather than repeated spot measurements.

The technology is being positioned to support a range of clinical and commercial applications, including chronic disease management, wound and post-surgical monitoring, and clinical research where continuous molecular-level data can improve decision-making.